The DOI matches its Crossref record; 79 of the 79 references it cites were found in a registry or an index.
2011: the immune hallmarks of cancer
Open accessAbstract
Ten years after the publication of the position paper "The hallmarks of cancer" (Hanahan and Weinberg Cell 100:57-70, 2000), it has become increasingly clear that mutated cells on their way to giving rise to a tumor have also to learn how to thrive in a chronically inflamed microenvironment, evade immune recognition, and suppress immune reactivity. Genetic and molecular definition of these three immune hallmarks of cancer offers the opportunity to learn how to deploy specific countermeasures to reverse the situation in favor of the immune system and, eventually, the patient. This new information could be channeled to address what seem to be the three major hallmarks for the immune control of cancer progression: effective procedures to activate immune reactivity; characterization of not-disposable oncoantigens; and counteraction of immune suppression.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Mantovani, A., Allavena, P., Sica, A., & Balkwill, F. (2008) · Nature · doi:10.1038/nature07205 · Cited by 11,399
Myeloid-derived-suppressor cells as regulators of the immune system
Gabrilovich, D. I., & Nagaraj, S. (2009) · Nature Reviews Immunology · doi:10.1038/nri2506 · Cited by 6,753
Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer
Kantoff, P. W., Higano, C. S., Shore, N. D., Berger, E. R., Small, E. J., Penson, D. F., Redfern, C. H., Ferrari, A. C., Dreicer, R., Sims, R. B., et al. (2010) · New England Journal of Medicine · doi:10.1056/nejmoa1001294 · Cited by 5,572 · cited 2×
“It is remarkable that a clinical trial of the first approved vaccine revealed significant correlations between patient survival and specific antibody titers, but not T-cell responses [80].”
BackgroundCuriel, T. J., Coukos, G., Zou, L., Alvarez, X., Cheng, P., Mottram, P., Evdemon-Hogan, M., Conejo-Garcia, J. R., Zhang, L., Burow, M., et al. (2004) · Nature Medicine · doi:10.1038/nm1093 · Cited by 5,151
Papillomaviruses and cancer: from basic studies to clinical application
zur Hausen, H. (2002) · Nature Reviews Cancer · doi:10.1038/nrc798 · Cited by 4,024
NF-κB: linking inflammation and immunity to cancer development and progression
Karin, M., & Greten, F. R. (2005) · Nature Reviews Immunology · doi:10.1038/nri1703 · Cited by 3,085
The Three Es of Cancer Immunoediting
Dunn, G. P., Old, L. J., & Schreiber, R. D. (2004) · Annual Review of Immunology · doi:10.1146/annurev.immunol.22.012703.104803 · Cited by 3,072
IFNγ and lymphocytes prevent primary tumour development and shape tumour immunogenicity
Shankaran, V., Ikeda, H., Bruce, A. T., White, J. M., Swanson, P. E., Old, L. J., & Schreiber, R. D. (2001) · Nature · doi:10.1038/35074122 · Cited by 2,896
Cancer-related inflammation, the seventh hallmark of cancer: links to genetic instability
Colotta, F., Allavena, P., Sica, A., Garlanda, C., & Mantovani, A. (2009) · Carcinogenesis · doi:10.1093/carcin/bgp127 · Cited by 2,890
IKKβ Links Inflammation and Tumorigenesis in a Mouse Model of Colitis-Associated Cancer
Greten, F. R., Eckmann, L., Greten, T. F., Park, J. M., Li, Z.-W., Egan, L. J., Kagnoff, M. F., & Karin, M. (2004) · Cell · doi:10.1016/j.cell.2004.07.013 · Cited by 2,433
NF-κB functions as a tumour promoter in inflammation-associated cancer
Pikarsky, E., Porat, R. M., Stein, I., Abramovitch, R., Amit, S., Kasem, S., Gutkovich-Pyest, E., Urieli-Shoval, S., Galun, E., & Ben-Neriah, Y. (2004) · Nature · doi:10.1038/nature02924 · Cited by 2,430
Interleukin-1 polymorphisms associated with increased risk of gastric cancer
El-Omar, E. M., Carrington, M., Chow, W.-H., McColl, K. E. L., Bream, J. H., Young, H. A., Herrera, J., Lissowska, J., Yuan, C.-C., Rothman, N., et al. (2000) · Nature · doi:10.1038/35006081 · Cited by 2,366
Grulich, A. E., van Leeuwen, M. T., Falster, M. O., & Vajdic, C. M. (2007) · The Lancet · doi:10.1016/s0140-6736(07)61050-2 · Cited by 2,323
CD4+CD25+ suppressor T cells: more questions than answers
Shevach, E. M. (2002) · Nature Reviews Immunology · doi:10.1038/nri821 · Cited by 2,110
Regulatory T cells, tumour immunity and immunotherapy
Zou, W. (2006) · Nature Reviews Immunology · doi:10.1038/nri1806 · Cited by 2,085
Immunosuppressive networks in the tumour environment and their therapeutic relevance
Zou, W. (2005) · Nature Reviews Cancer · doi:10.1038/nrc1586 · Cited by 2,057
The Concept of Immunological Surveillance
Burnet, F. M. (2015) · Progress in Tumor Research · doi:10.1159/000386035 · Cited by 1,656
Adaptive immunity maintains occult cancer in an equilibrium state
Koebel, C. M., Vermi, W., Swann, J. B., Zerafa, N., Rodig, S. J., Old, L. J., Smyth, M. J., & Schreiber, R. D. (2007) · Nature · doi:10.1038/nature06309 · Cited by 1,436
Monoclonal antibodies: versatile platforms for cancer immunotherapy
Weiner, L. M., Surana, R., & Wang, S. (2010) · Nature Reviews Immunology · doi:10.1038/nri2744 · Cited by 1,283
Maeda, S., Kamata, H., Luo, J.-L., Leffert, H., & Karin, M. (2005) · Cell · doi:10.1016/j.cell.2005.04.014 · Cited by 1,164
Regulatory T cells exert checks and balances on self tolerance and autoimmunity
Wing, K., & Sakaguchi, S. (2010) · Nature Immunology · doi:10.1038/ni.1818 · Cited by 1,107
New insights into the regulation of T cells by γc family cytokines
Rochman, Y., Spolski, R., & Leonard, W. J. (2009) · Nature Reviews Immunology · doi:10.1038/nri2580 · Cited by 1,053
Development trends for human monoclonal antibody therapeutics
Nelson, A. L., Dhimolea, E., & Reichert, J. M. (2010) · Nature Reviews Drug Discovery · doi:10.1038/nrd3229 · Cited by 1,026
Mice deficient in tumor necrosis factor-α are resistant to skin carcinogenesis
Moore, R. J., Owens, D. M., Stamp, G., Arnott, C., Burke, F., East, N., Holdsworth, H., Turner, L., Rollins, B., Pasparakis, M., et al. (1999) · Nature Medicine · doi:10.1038/10552 · Cited by 839
Weinstein, I. B., & Joe, A. (2008) · Cancer Research · doi:10.1158/0008-5472.can-07-3293 · Cited by 805
Ghiringhelli, F., Puig, P. E., Roux, S., Parcellier, A., Schmitt, E., Solary, E., Kroemer, G., Martin, F., Chauffert, B., & Zitvogel, L. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20050463 · Cited by 776
Cuzick, J., Otto, F., Baron, J. A., Brown, P. H., Burn, J., Greenwald, P., Jankowski, J., La Vecchia, C., Meyskens, F., Senn, H. J., et al. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70035-x · Cited by 714
Mantovani, A. (2009) · Nature · doi:10.1038/457036b · Cited by 643
Cancer vaccines: between the idea and the reality
Finn, O. J. (2003) · Nature Reviews Immunology · doi:10.1038/nri1150 · Cited by 636
Decreased Incidence of Hepatocellular Carcinoma in Hepatitis B Vaccinees: A 20-Year Follow-up Study
Chang, M.-H., You, S.-L., Chen, C.-J., Liu, C.-J., Lee, C.-M., Lin, S.-M., Chu, H.-C., Wu, T.-C., Yang, S.-S., Kuo, H.-S., et al. (2009) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/djp288 · Cited by 635
The therapeutic effect of anti-HER2/neu antibody depends on both innate and adaptive immunity
Park, S., Jiang, Z., Mortenson, E. D., Deng, L., Radkevich-Brown, O., Yang, X., Sattar, H., Wang, Y., Brown, N. K., Greene, M., et al. (2010) · Cancer Cell · doi:10.1016/j.ccr.2010.06.014 · Cited by 577 · cited 1×
“mAb against Class I and Class II oncoantigens not only functionally inhibit the activity of their targets and recruit antibody-dependent killer mechanisms and complement-dependent reactions but also recruit the host adaptive response and act to some extent as a vaccine [84, 85].”
BackgroundTumour immunity: effector response to tumour and role of the microenvironment
Mantovani, A., Romero, P., Palucka, A. K., & Marincola, F. M. (2008) · The Lancet · doi:10.1016/s0140-6736(08)60241-x · Cited by 537
Myeloid-derived suppressor cells: more mechanisms for inhibiting antitumor immunity
Ostrand-Rosenberg, S. (2010) · Cancer Immunology, Immunotherapy · doi:10.1007/s00262-010-0855-8 · Cited by 521
Interactions between lymphocytes and myeloid cells regulate pro- versus anti-tumor immunity
DeNardo, D. G., Andreu, P., & Coussens, L. M. (2010) · Cancer and Metastasis Reviews · doi:10.1007/s10555-010-9223-6 · Cited by 515
Sokal, E. M., Hoppenbrouwers, K., Vandermeulen, C., Moutschen, M., Léonard, P., Moreels, A., Haumont, M., Bollen, A., Smets, F., & Denis, M. (2007) · The Journal of Infectious Diseases · doi:10.1086/523813 · Cited by 426
Regulatory T-cell inhibition versus depletion: the right choice in cancer immunotherapy
Colombo, M. P., & Piconese, S. (2007) · Nature Reviews Cancer · doi:10.1038/nrc2250 · Cited by 407
OX40 triggering blocks suppression by regulatory T cells and facilitates tumor rejection
Piconese, S., Valzasina, B., & Colombo, M. P. (2008) · The Journal of Experimental Medicine · doi:10.1084/jem.20071341 · Cited by 405
Recruitment of latent pools of high-avidity CD8+ T cells to the antitumor immune response
Ercolini, A. M., Ladle, B. H., Manning, E. A., Pfannenstiel, L. W., Armstrong, T. D., Machiels, J.-P. H., Bieler, J. G., Emens, L. A., Reilly, R. T., & Jaffee, E. M. (2005) · The Journal of Experimental Medicine · doi:10.1084/jem.20042167 · Cited by 399
Tumor Development after 3-Methylcholanthrene in Immunologically Deficient Athymic-Nude Mice
Stutman, O. (1974) · Science · doi:10.1126/science.183.4124.534 · Cited by 356
Vaccines for tumour prevention
Lollini, P.-L., Cavallo, F., Nanni, P., & Forni, G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1815 · Cited by 340
Self-citationAn update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results
Schiller, J. T., Castellsagué, X., Villa, L. L., & Hildesheim, A. (2008) · Vaccine · doi:10.1016/j.vaccine.2008.06.002 · Cited by 334
Ferris, R. L., Jaffee, E. M., & Ferrone, S. (2010) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.6360 · Cited by 320
Control of immune response by amino acid metabolism
Grohmann, U., & Bronte, V. (2010) · Immunological Reviews · doi:10.1111/j.1600-065x.2010.00915.x · Cited by 308
MHC antigens and tumor escape from immune surveillance
(2001) · Advances in Cancer Research · doi:10.1016/s0065-230x(01)83005-0 · Cited by 305
Müller-Hermelink, N., Braumüller, H., Pichler, B., Wieder, T., Mailhammer, R., Schaak, K., Ghoreschi, K., Yazdi, A., Haubner, R., Sander, C. A., et al. (2008) · Cancer Cell · doi:10.1016/j.ccr.2008.04.001 · Cited by 302
Dendritic Cell Subsets Differentially Regulate Angiogenesis in Human Ovarian Cancer
Curiel, T. J., Cheng, P., Mottram, P., Alvarez, X., Moons, L., Evdemon-Hogan, M., Wei, S., Zou, L., Kryczek, I., Hoyle, G., et al. (2004) · Cancer Research · doi:10.1158/0008-5472.can-04-1272 · Cited by 297
Melani, C., Chiodoni, C., Forni, G., & Colombo, M. P. (2003) · Blood · doi:10.1182/blood-2003-01-0190 · Cited by 295
Self-citationWelters, M. J. P., Kenter, G. G., de Vos van Steenwijk, P. J., Löwik, M. J. G., Berends-van der Meer, D. M. A., Essahsah, F., Stynenbosch, L. F. M., Vloon, A. P. G., Ramwadhdoebe, T. H., Piersma, S. J., et al. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1006500107 · Cited by 239
Nanni, P., Nicoletti, G., De Giovanni, C., Landuzzi, L., Di Carlo, E., Cavallo, F., Pupa, S. M., Rossi, I., Colombo, M. P., Ricci, C., et al. (2001) · The Journal of Experimental Medicine · doi:10.1084/jem.194.9.1195 · Cited by 230
Self-citationWhat are the hallmarks of cancer?
Lazebnik, Y. (2010) · Nature Reviews Cancer · doi:10.1038/nrc2827 · Cited by 227
Aging, Longevity, Inflammation, and Cancer
CARUSO, C., LIO, D., CAVALLONE, L., & FRANCESCHI, C. (2004) · Annals of the New York Academy of Sciences · doi:10.1196/annals.1322.001 · Cited by 218
Therapeutic targeting of myeloid-derived suppressor cells
Ugel, S., Delpozzo, F., Desantis, G., Papalini, F., Simonato, F., Sonda, N., Zilio, S., & Bronte, V. (2009) · Current Opinion in Pharmacology · doi:10.1016/j.coph.2009.06.014 · Cited by 206
Much Ado about Adenosine: Adenosine Synthesis and Function in Regulatory T Cell Biology
Ernst, P. B., Garrison, J. C., & Thompson, L. F. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.1000108 · Cited by 199
Inflammation and breast cancer
Constantinou, C., & Fentiman, I. S. (2013) · Breast Cancer Management · doi:10.2217/bmt.13.26 · Cited by 196
Molecular mechanisms of MHC class I abnormalities and APM components in human tumors
Seliger, B. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0515-4 · Cited by 182
Inflammation, ageing and cancer
Vasto, S., Carruba, G., Lio, D., Colonna‐Romano, G., Bona, D. D., Candore, G., & Caruso, C. (2008) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2008.06.003 · Cited by 139
The anaplastic lymphoma kinase is an effective oncoantigen for lymphoma vaccination
Chiarle, R., Martinengo, C., Mastini, C., Ambrogio, C., d’Escamard, V., Forni, G., & Inghirami, G. (2008) · Nature Medicine · doi:10.1038/nm1769 · Cited by 129
Self-citationRees, L., Tizard, E. J., Morgan, A. J., Cubitt, W. D., Finerty, S., Oyewole-Eletu, T., Owen, K., Royed, C., Stevens, S. J. C., Shroff, R. C., et al. (2009) · Transplantation · doi:10.1097/tp.0b013e3181b9d918 · Cited by 127
Evolving novel anti-HER2 strategies
Jones, K. L., & Buzdar, A. U. (2009) · The Lancet Oncology · doi:10.1016/s1470-2045(09)70315-8 · Cited by 112
Kmieciak, M., Knutson, K. L., Dumur, C. I., & Manjili, M. H. (2007) · European Journal of Immunology · doi:10.1002/eji.200636639 · Cited by 108
Park, J. M., Terabe, M., Sakai, Y., Munasinghe, J., Forni, G., Morris, J. C., & Berzofsky, J. A. (2005) · The Journal of Immunology · doi:10.4049/jimmunol.174.7.4228 · Cited by 92
Self-citationImmunoprevention of Mammary Carcinoma in HER-2/ neu Transgenic Mice Is IFN-γ and B Cell Dependent
Nanni, P., Landuzzi, L., Nicoletti, G., Giovanni, C. D., Rossi, I., Croci, S., Astolfi, A., Iezzi, M., Carlo, E. D., Musiani, P., et al. (2004) · The Journal of Immunology · doi:10.4049/jimmunol.173.4.2288 · Cited by 91
Self-citationNanni, P., Pupa, S. M., Nicoletti, G., Giovanni, C. D., Landuzzi, L., Rossi, I., Astolfi, A., Ricci, C., Vecchi, R. D., Invernizzi, A. M., et al. (2000) · International Journal of Cancer · Cited by 86
Self-citationSchuster, S. J., Neelapu, S. S., Gause, B. L., Muggia, F. M., Gockerman, J. P., Sotomayor, E. M., Winter, J. N., Flowers, C. R., Stergiou, A. M., & Kwak, L. W. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.2 · Cited by 85
Beatty, P. L., Narayanan, S., Gariépy, J., Ranganathan, S., & Finn, O. J. (2010) · Cancer Prevention Research · doi:10.1158/1940-6207.capr-09-0194 · Cited by 83
Schwartzentruber, D. J., Lawson, D. J., Richards, J. M., Conry, R. M., Miller, D. M., Triesman, J., Gailani, F., Riley, L., Vena, D. A., & Hwu, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.15_suppl.cra9011 · Cited by 83
Norell, H., Carlsten, M., Ohlum, T., Malmberg, K., Masucci, G. V., Schedvins, K., Altermann, W., Handke, D., Atkins, D., Seliger, B., et al. (2006) · Cancer Research · doi:10.1158/0008-5472.can-06-0029 · Cited by 66
Vertuani, S., Triulzi, C., Roos, A., Charo, J., Norell, H., Lemonnier, F. A., Pisa, P., Seliger, B., & Kiessling, R. W. (2008) · Cancer Immunology Immunotherapy · doi:10.1007/s00262-008-0587-1 · Cited by 61
Are oncoantigens suitable targets for anti-tumour therapy?
Cavallo, F., Calogero, R., & Forni, G. (2007) · Nature reviews. Cancer · doi:10.1038/nrc2208 · Cited by 55
Self-citationWarren, M. A., Shoemaker, S. F., Shealy, D. J., Bshara, W., & Ip, M. M. (2009) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-09-0358 · Cited by 53
Schwartzentruber, D. J., Lawson, D. J., Richards, J., Conry, R. M., Miller, D., Triesman, J., Gailani, F., Riley, L. B., Vena, D. A., & Hwu, P. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.18_suppl.cra9011 · Cited by 51
Vaccines and Other Immunological Approaches for Cancer Immunoprevention
Lollini, P., Nicoletti, G., Landuzzi, L., Cavallo, F., Forni, G., Giovanni, C. D., & Nanni, P. (2011) · Current Drug Targets · doi:10.2174/138945011798184146 · Cited by 42
Self-citationSchuster, S. J., Neelapu, S. S., Gause, B. L., Muggia, F. M., Gockerman, J. P., Sotomayor, E. M., Winter, J. N., Flowers, C. R., Stergiou, A. M., & Kwak, L. W. (2009) · Journal of Clinical Oncology · doi:10.1200/jco.2009.27.18_suppl.2 · Cited by 39
Sangaletti, S., Tripodo, C., Ratti, C., Piconese, S., Porcasi, R., Salcedo, R., Trinchieri, G., Colombo, M. P., & Chiodoni, C. (2010) · Cancer Research · doi:10.1158/0008-5472.can-10-0471 · Cited by 37
Cipriani, B., Fridman, A., Bendtsen, C., Dharmapuri, S., Mennuni, C., Pak, I., Mesiti, G., Forni, G., Monaci, P., Bagchi, A., et al. (2008) · Human Gene Therapy · doi:10.1089/hum.2007.127 · Cited by 36
Self-citationCalogero, R., Cordero, F., Forni, G., & Cavallo, F. (2007) · Breast Cancer Research · doi:10.1186/bcr1745 · Cited by 35
Self-citationMyeloid cells functioning in tumor vascularization as a novel therapeutic target
McLean, K., & Buckanovich, R. J. (2008) · Translational research · doi:10.1016/j.trsl.2007.11.002 · Cited by 23
Nicoletti, G., Giovanni, C. D., Lollini, P., et al. (1989) · European Journal of Cancer and Clinical Oncology · doi:10.1016/0277-5379(89)90074-6 · Cited by 21
Self-citation
Cited by
Rivera, C. (2015) · PubMed · doi:10.5281/zenodo.192487 · Cited by 818
Exosome-Based Cell-Cell Communication in the Tumor Microenvironment
Maia, J., Caja, S., Strano Moraes, M. C., Couto, N., & Costa-Silva, B. (2018) · Frontiers in Cell and Developmental Biology · doi:10.3389/fcell.2018.00018 · Cited by 666
Exosomes and their roles in immune regulation and cancer
Greening, D. W., Gopal, S. K., Xu, R., Simpson, R. J., & Chen, W. (2015) · Seminars in Cell & Developmental Biology · doi:10.1016/j.semcdb.2015.02.009 · Cited by 597
Regulating tumor suppressor genes: post-translational modifications
Chen, L., Liu, S., & Tao, Y. (2020) · Signal Transduction and Targeted Therapy · doi:10.1038/s41392-020-0196-9 · Cited by 449
Targeting Myeloid-Derived Suppressor Cells to Bypass Tumor-Induced Immunosuppression
Fleming, V., Hu, X., Weber, R., Nagibin, V., Groth, C., Altevogt, P., Utikal, J., & Umansky, V. (2018) · Frontiers in Immunology · doi:10.3389/fimmu.2018.00398 · Cited by 443
Metadata
- Authors
- Cavallo, F., De Giovanni, C., Nanni, P., Forni, G., & Lollini, P.-L.
- Venue
- Cancer Immunology, Immunotherapy
- Published
- 2011-01-26
- Volume
- 60
- Issue
- 3
- Pages
- 319-326
- ISSN
- 0340-7004 (ISSN-L)
- 1432-0851
- OpenAlex
- W2088481746
- Cited by
- 415
- References
- 79
- FWCI
- 14.75
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.